Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: A report of two patients

8Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cyclic thrombocytopenia (CTP), characterized by periodic oscillations of the platelet count with cycles of 20-40 days, is a rare disorder that has demographic and clinical features similar to immune thrombocytopenic purpura (ITP) [1]. Like ITP, the pathogenesis can involve both accelerated platelet destruction and insufficient platelet production [1]. However, CTP appears to be less responsive to conventional therapies used for ITP [1]. Thrombopoietin (TPO)-mimetic agents have recently been documented to be effective for most patients with ITP [2-5]. We present two women with CTP who have been effectively treated with TPO-mimetic agents following failure of multiple treatments for ITP. The first report is an 11 year follow-up of a patient whose initial 1 year of treatment with recombinant pegylated human megakaryocyte growth and development factor (PEG-rHuMGDF) has been previously reported [6]. She was successfully treated with PEG-rHuMGDF for 12 years, and is currently treated with romiplostim. The second patient has been successfully treated with romiplostim for 3 years. TPO-mimetic agents can provide effective long-term treatment for patients with severe and symptomatic CTP.

Cite

CITATION STYLE

APA

Bose, P., Hussein, K. K., Terrell, D. R., Berger, D., Rice, L., & George, J. N. (2009). Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: A report of two patients. American Journal of Hematology, 84(7), 459–461. https://doi.org/10.1002/ajh.21435

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free